ストックスクリーナーアプリを入手
3.73
0.40%
-0.01
前日終値:
$3.74
開ける：
$3.73
24時間の取引高:
96,249
Relative Volume:
0.05
時価総額：
$452.26M
収益：
$7.83M
当期純損益:
$-64.92M
株価収益率:
-7.0417
EPS:
-0.5297
ネットキャッシュフロー:
$-47.22M
1週間 パフォーマンス:
+1.50%
1か月 パフォーマンス:
+14.26%
6か月 パフォーマンス:
+105.80%
1年 パフォーマンス:
+135.76%
1日の値動き範囲:
$3.67
$3.77
1週間の範囲:
$3.36
$3.835
52週間の値動き範囲:
$1.05
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Compare ACRS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.735 | 452.87M | 7.83M | -64.92M | -47.22M | -0.5297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.54 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.95 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
713.98 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
290.76 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 再開されました | Piper Sandler | Overweight |
| 2025-05-28 | 開始されました | Wedbush | Outperform |
| 2025-03-18 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-12-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-11-19 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-19 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 開始されました | Evercore ISI | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2022-10-06 | 開始されました | BTIG Research | Buy |
| 2021-07-23 | 再開されました | Jefferies | Buy |
| 2021-06-15 | 開始されました | Piper Sandler | Overweight |
| 2021-04-21 | 開始されました | H.C. Wainwright | Buy |
| 2019-10-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 開始されました | SVB Leerink | Outperform |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2018-02-09 | 開始されました | Guggenheim | Buy |
| 2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 開始されました | Leerink Partners | Outperform |
| 2016-09-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-06-10 | 開始されました | Guggenheim | Buy |
| 2015-11-02 | 開始されました | Citigroup | Buy |
| 2015-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Aclaris Therapeutics Inc (ACRS) 最新ニュース
Research Analysts Offer Predictions for ACRS FY2027 Earnings - MarketBeat
Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aclaris Therapeutics to Present New Data on Atopic Dermatitis Drug at EADV Congress - MSN
Helus Pharma taps veteran Jill Conwell to steer people strategy for growth - Stock Titan
Aclaris Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information as of March 10, 2026 - Minichart
Aclaris Therapeutics Raises $20 Million in Equity Financing - TipRanks
Aclaris Therapeutics sells 5.7M shares for $20.0M to institutional buyers - TradingView
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Aug Intraday: Whats the beta of Aclaris Therapeutics Inc stock2026 Weekly Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
ACRS: Multiple late-stage immunology assets advance with funding secured through Q4 2028 - TradingView
Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference - MarketBeat
Aclaris Therapeutics Gears Up For New Trials Despite Financial Hurdles - StocksToTrade
Aclaris Therapeutics Pushes Forward with Promising Clinical Trials Amidst Financial Highlights - timothysykes.com
Aclaris Therapeutics, Inc. 8-K SEC Filing Summary – Company Information & Details (March 9, 2026) - Minichart
Aclaris Therapeutics Raises Capital via Institutional Stock Sale - TipRanks
Aclaris Therapeutics sells 12.7M shares for $39.8M under ATM offering - TradingView
Institutional investors buy 12.7M Aclaris (ACRS) shares for $39.8M - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Can Aclaris Therapeutics Inc. (8AT) stock hit consensus price targetsTrade Risk Assessment & Verified Short-Term Plans - Naître et grandir
Investment Recap: What is Aclaris Therapeutics Incs P E ratio telling usJuly 2025 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
Aclaris Reports 2025 Financial Results and Clinical Trial Updates - MyChesCo
Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma - MyChesCo
[Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity - Stock Titan
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference - marketscreener.com
Technical Analysis: Why is Aclaris Therapeutics Inc stock going upTrade Risk Assessment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline - Investing.com Canada
Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates - Investing.com Australia
Craig-Hallum Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS) - The Globe and Mail
Aclaris: Q4 Earnings Snapshot - theheraldreview.com
Aclaris Therapeutics (NASDAQ:ACRS) Announces Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Aclaris Therapeutics (NASDAQ: ACRS) outlines deep immunology pipeline and 2025 losses - Stock Titan
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference - MarketBeat
Aclaris at Oppenheimer Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Aclaris at Oppenheimer Conference: Strategic Pipeline Focus - Investing.com India
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Aclaris Therapeutics (ACRS) narrows 2025 loss and details 2026 trial milestones - Stock Titan
Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Aclaris Therapeutics Reports Positive Interim Phase 1a Results for ATI-052 and Advances Pipeline with Upcoming Trials and IND Application - Quiver Quantitative
Mouse hair regrows 93% in Aclaris alopecia study, 2025 loss shrinks - Stock Titan
Aclaris: Fourth Quarter Financial Overview - Bitget
Aclaris starts phase 1b trial of ATI-052 in asthma patients - Investing.com Australia
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 - The Manila Times
Aclaris tests experimental asthma antibody in new human trial - Stock Titan
Aclaris Therapeutics Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Market Rankings: Whats the beta of Seacoast Banking Corporation of Florida stockJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Will Aclaris Therapeutics Inc. stock recover faster than peersWeekly Market Report & Community Driven Trade Alerts - mfd.ru
Aclaris Therapeutics (ACRS) Projected to Post Earnings on Thursday - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aclaris Therapeutics Inc (ACRS) 財務データ
収益
当期純利益
現金流量
EPS
0.44%
大文字化:
|
ボリューム (24 時間):